

1
2
3
4
5 **Female Resistance to Pneumonia Identifies Lung Macrophage Nitric Oxide**
6 **Synthase-3 as a Therapeutic Target**
7

8 **Authors:**

9 Z. Yang¹, Y-C. Huang², H. Koziel³, R. de Crom⁴, H. Ruetten⁵, P. Wohlfart⁵, R.W. Thomsen⁶, J.
10 A. Kahlert⁶, H.T. Sorensen⁶, S. Jozefowski⁷, A. Colby¹, L. Kobzik^{1,8*}

11 **Affiliations:**

12
13 ¹Dept of Environmental Health, Harvard School of Public Health, Boston, MA

14 ²Human Studies Division, National Health and Environmental Effects Research Laboratory, US
15 Environmental Protection Agency, Chapel Hill, NC

16
17 ³Division of Pulmonary, Critical Care and Sleep Medicine, Beth Israel Deaconness Medical
18 Center, Boston, MA

19 ⁴Department of Cell Biology & Genetics, Erasmus University Medical Center, Rotterdam, The
20 Netherlands

21 ⁵Sanofi R&D Diabetes Division, Frankfurt/Main, Germany

22 ⁶Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark

23 ⁷Department of Immunology, Jagiellonian University Medical College, Kraków, Poland

24 ⁸Department of Pathology, Brigham & Women's Hospital, Boston, MA

25 *To whom correspondence should be addressed: lkobzik@hsph.harvard.edu
26

27 **Competing interests:** H. Ruetten and P. Wohlfart are named as inventors on patents (US
28 7,179,839; 8,309,608, held by Sanofi, Inc.) describing AVE3085 as a useful compound for
29 cardiovascular indications.

30 **One Sentence Summary:** Activation of lung macrophage nitric oxide synthase-3 improves both
31 bacterial clearance and outcome in primary and secondary pneumonia models.
32

Abstract:

To identify new approaches to enhance innate immunity to bacterial pneumonia, we investigated the natural experiment of gender differences in resistance to infections. Female and estrogen-treated male mice show greater resistance to pneumococcal pneumonia, seen as greater bacterial clearance, diminished lung inflammation and better survival. In vitro, lung macrophages from female mice and humans show better killing of ingested bacteria. Inhibitors and genetically altered mice identify a critical role for estrogen-mediated activation of lung macrophage nitric oxide synthase-3 (NOS3). Epidemiologic data show decreased hospitalization for pneumonia in women receiving estrogen or statins (known to activate NOS3). Pharmacologic targeting of NOS3 with statins or another small-molecule compound (AVE3085) enhanced macrophage bacterial killing, improved bacterial clearance and increased host survival in both primary and secondary (post-influenza) pneumonia. The data identify a novel mechanism for host defense via NOS3 and suggest a potential therapeutic strategy to reduce secondary bacterial pneumonia after influenza.

Introduction

Bacterial pneumonia remains a major cause of morbidity and mortality (1, 2). One approach to the problem might be to enhance innate immunity to infection. Normal host defenses are already quite robust, albeit imperfect, as they keep the incidence of pneumonia much lower than possible given the normal nocturnal aspiration of nasopharyngeal bacteria, e.g. *Strep. pneumoniae* (3-5). The resident alveolar macrophage (AM) functions as a ‘first responder’ phagocyte, ingesting and killing inhaled bacteria (6-8). The importance of this function of AMs is indicated by greater susceptibility to infection and diminished bacterial clearance after their experimental depletion (9, 10) or their impairment by clinical risk factors such as recent influenza infection (11).

To guide investigation of possible targets to improve or restore lung macrophage antibacterial function, we sought to exploit the natural experiment of gender differences in resistance to infections. Experimental models find that female mice show greater systemic resistance to pneumococci (12, 13) and to many other (but not all) pathogens(14). Epidemiologic studies of human pneumonia observe a greater incidence of community-acquired pneumonia in males (15), and show that males are at greater risk than females for pneumonia after admission to hospital after adjusting for other risk factors such as smoking and alcohol use(16-18).

We chose to address this problem by using a model of pneumococcal infection that approximates the frequent challenge to lung defenses by small numbers of bacteria, and comparing responses in male and female mice. We identified greater female resistance to infection, mediated in large part by estrogen-dependent activation of constitutive AM nitric oxide synthase-3 (NOS3). Pharmacologic agents that enhance NOS3 function improved resistance in mouse models of both primary lung infection and post-influenza secondary pneumonia, suggesting a strategy to enhance resistance to common and serious lung infections.

Results

Superior resistance of female mice to pneumococcal pneumonia

We tested effects of a relatively small bacteria inoculum size to simulate the common, low-level challenge to the lungs from aspiration of upper airway bacteria. Female mice and

estrogen-treated male mice showed greater clearance of bacteria from the lungs and less acute inflammation (neutrophil influx) compared to normal or sham-treated males 24 hours after inoculation of *Strep. pneumoniae* (Figs. 1A & B). Pilot experiments compared efficiency of delivery in male vs female mice by measuring bacterial CFUs 5 minutes after instillation. The results showed slightly greater initial bacterial loads in female mice ($p < .02$, $n = 12/\text{group}$), indicating that the female advantage does not reflect a lower inoculum due to anatomic or size differences. Greater female resistance was also observed in longer duration survival studies (Fig. 1C). The gender differences we observed with 10^5 colony-forming units (CFU) were not seen if a lethal inoculum (~11-fold higher) of bacteria was used, as both genders showed markedly increased inflammation and lung cytokine levels (Figs. 1D-G).

Superior bacterial killing by female alveolar macrophages

To compare the innate antibacterial function of alveolar macrophages from both genders, we measured phagocytosis and killing of pneumococci in vitro by AMs from normal mice and humans. Analysis of bacterial binding and internalization showed no differences between male and female murine AMs (Fig. 2A, B; similar data with human AMs not shown). In contrast, killing of internalized bacteria was greater in female AMs than male AMs in mouse samples challenged with *Strep.pneumoniae*, as well as with other lung pathogens *Staph. aureus*, and *E. Coli* (Figs. 2C-E). Similarly, normal human female AMs showed greater killing of ingested pneumococci than their male counterparts (Fig. 2F).

NOS3 mediates the female advantage

Mechanisms for killing phagocytosed bacteria include production of reactive oxygen species (ROS), e.g., superoxide produced by NADPH oxidase, and reactive nitrogen intermediates (RNI), e.g. nitric oxide produced by nitric oxide synthases (NOS). We first used mice genetically deficient in NADPH oxidase (19) to more directly evaluate the importance of this pathway in vivo. Bacterial clearance in NADPH oxidase-null mice was significantly impaired, but did not eliminate the gender difference, since both male and female mice were affected approximately equally (Fig. 3A). Additional experiments showed no difference in generation of ROS by male and female AMs stimulated to undergo a respiratory burst in vitro

(Figure 1-figure supplement 1). Similarly, quantitative real-time PCR using primers for NADPH oxidase components (phox22, 47, 91) or myeloperoxidase showed no difference in expression (data not shown).

To explore the potential role of RNI, we tested the effect of NOS inhibitors on bacterial killing by female murine AMs in vitro. As shown in Fig. 3B, the non-selective NOS blocker nitro-L-arginine (NLA) caused substantial inhibition of female AM killing, while its stereoisomer control NDA and the inducible NOS (iNOS or NOS2)-specific inhibitor 1400W had no effect. This suggested a role for another NOS isoform, namely the constitutively expressed endothelial type NOS3 found in alveolar and other macrophages (20-22). This postulate was directly tested using mice genetically deficient in NOS3. In vitro, deficiency in NOS3 did not alter killing by male macrophages, but completely abolished the female advantage in bacterial killing (Fig. 3C). In vivo, absence of NOS3 had minimal effects on male clearance of bacteria, but reduced the female advantage by ~50% (Fig. 3D). Genetic deletion of NOS3 greatly reduced survival in female mice with pneumonia (Fig. 3E), and transgenic overexpression of NOS3 increased bacterial clearance in male mice (Fig. 3F), supporting the functional importance of this pathway. The 24 hour in vivo bacterial clearance assay provides enough time for induction of NOS2, which is known to mediate macrophage antimicrobial function in rodents (23). To test the contribution of this isoform, we measured bacterial clearance in NOS2-deficient mice and in mice treated with the NOS2 inhibitor 1400W. The data show that male mice do rely on NOS2, since clearance of pneumococci was markedly worse in NOS2-deficient or 1400W-treated mice compared to controls (Figs 3G & H). In contrast, female mice showed a trend for improved clearance when *Nos2* was genetically deleted (Fig 3G); similar results were seen in wild-type female mice after pharmacologic inhibition of NOS2 (Fig. 3H). Since NO itself can inhibit NOS3 function (24, 25), the data suggest that low-level basal NOS2 or NOS2 induction actually hampers the beneficial activity of NOS3 in females.

Estrogen effects on NOS3

To facilitate biochemical analysis of estrogen effects on macrophage function, we tested the effect of estrogen on bacterial uptake and killing by macrophage cell lines. The cell lines were cultured using hormone-free serum. After estrogen treatment, the macrophage cell lines J744A.1 (murine) and U937 (human) showed increased killing of internalized bacteria (Fig 4A,

B), although no differences in binding or internalization of bacteria were observed (data not shown). This increased killing capacity was inhibited by the NOS inhibitors NLA or L-NMMA, but not their stereoisomer controls. After estrogen treatment (0.2 ng/ml, 1 hour), we measured slight, albeit consistent, increases in nitrite production by bacteria-challenged J774A.1 macrophages ($p < .01$, paired t-test, $n = 13$). The increase (~ 25 pmoles NO_2^- per 10^6 macrophages) is consistent with the small levels attributed to NOS3 activity in normal rat AMs (~ 70 pmoles/ 10^6 cells (21)) and with the rate of NO release observed upon estrogen stimulation of human monocytes (26).

Studies of NOS3 in endothelial cell biology have identified rapid activation via phosphorylation of NOS3 at serine 1177 (27), and have shown that estrogen mediates this activation via specific signaling cascades, such as phospho-inositol-3 kinase and protein kinase B, also known as Akt, (28, 29). To investigate the pathway in macrophages, we cultured J774A.1 macrophages in hormone-free serum. Western blot analysis of responses after addition of estrogen to J774A.1 cells showed rapid phosphorylation of Akt and NOS3 in response to estrogen (Fig. 4C; fold-increase 1.7 ± 0.3 , 1.7 ± 0.1 , respectively, $n = 4-5$, $p < .01$) and basally increased levels of pNOS3 and pAkt in normal female mouse AMs compared to male AMs (Fig. 4C, fold-increase 1.7 ± 0.4 , 1.5 ± 0.2 , pAkt and pNOS3 respectively, $n = 2-3$, $p < .01$). The Western blot analysis also shows that the amount of NOS3 in the macrophage cell line and primary AMs is quite low, at least 2 orders of magnitude lower than present in the positive control bEnd.1 endothelial cell line samples. A role for PI3K in the signaling cascade was supported by the decrease in pAkt levels, either basally or after E2-treatment, in J774A.1 macrophages treated with the inhibitor wortmannin (Fig. 4D; fold increase 2.3 ± 0.2 , 1.04 ± 0.5 , pAkt after E2 or E2 + wortmannin, respectively, $n = 2-3$, $p < .05$).

To test this pathway more directly, we also used the Akt inhibitor, 1L-6-hydroxymethyl-chiro-inositol 2-(R)-2-O-methyl-3-O-octadecylcarbonate (30) to test whether it would block macrophage killing of pneumococci. This agent did not alter bacterial binding or internalization (not shown). As illustrated in Fig. 4E, Akt inhibition completely abrogated estrogen-mediated enhanced killing, supporting a functional role for Akt in estrogen-mediated activation of macrophages.

To begin testing of the translational potential of targeting NOS3, we first tested whether local delivery of estrogen to the lungs would improve resistance to bacterial pneumonia. We

found that aerosol treatment of male mice before challenge with pneumococci improved clearance of bacteria (Fig. 4F). This was especially true if we used an estradiol conjugated to albumin, which acts to slow absorption of this lipophilic hormone (systemic uptake being the basis for a form of aerosolized estrogen-replacement therapy formerly used in menopausal women (31)). Populations at risk for localized outbreaks of primary pneumococcal pneumonia include elderly (post-menopausal) nursing home residents (32). We evaluated bacterial clearance in a mouse model of menopause that gradually develops several weeks after surgical ovariectomy (33). We found a gradual decline in bacterial clearance in ovariectomized female mice to normal male levels at 10 weeks after ovariectomy; aerosolized estrogen treatment of ovariectomized mice reversed this decline and restored the normal, superior female clearance capacity (Fig. 4G).

Targeting NOS3 in primary pneumococcal pneumonia

Statins can increase levels of NOS3 (34), and have been associated with beneficial effects on incidence of hospitalization for pneumonia and subsequent mortality (35, 36). To study possible effects on innate immunity and initial resistance to pneumonia, we measured the effects of statin therapy and estrogen-replacement therapy on the incidence of hospitalization with pneumonia in a large well-defined female human population in Denmark between 1997 and 2012. Table 1 shows the characteristics of 28,576 female subjects with first-time hospitalized pneumonia and 142,880 age-matched female population control subjects. The unadjusted OR results in Table 2 indicate that in crude analyses, estrogen users had a similar pneumonia hospitalization risk than estrogen non-users, and statin users had a slightly higher pneumonia risk than statin non-users. After controlling for comorbidity and other confounding factors associated with drug use, we found that receiving statin therapy reduced incidence of pneumonia requiring hospitalization in females. In addition, estrogen-replacement therapy was associated with a similar reduction, and women receiving both statin and estrogen therapy showed an even greater reduction in pneumonia risk (adjusted OR 0.67, 95% CI: 0.60-0.75).

To investigate statin effects on macrophage interaction with bacteria, we first found that in vitro treatment of macrophages for 1-3 hours with mevastatin led to increased levels of NOS3 and its phosphorylated isoform (Fig 5A; fold-increase 2.0 ± 0.2 , 1.7 ± 0.6 , pNOS3, NOS3, 3h after mevastatin, respectively, $n = 2-3$, $p < .05$). This was associated with killing of internalized bacteria (Fig. 5B). We then measured in vivo clearance of pneumococci in mice treated with statins, and found improved clearance in both genders, but this improvement was not seen when mice deficient in NOS3 were used (Fig. 5C). Male mice treated with statins showed improved survival with pneumococcal pneumonia (Fig. 5D).

AVE3085 is a small molecule compound that increases NOS3 mRNA and protein levels by mechanisms distinct from statins (e.g., by enhancing transcription), and may provide a more NOS3-specific therapeutic option (37). We found that AVE3085 treatment improved bacterial killing by macrophages in vitro (Fig. 5E) and that mice treated with AVE3085 either by oral or subcutaneous administration showed substantially increased clearance of pneumococci in vivo, an effect not observed in *Nos3* $-/-$ mice (Fig. 5F).

Targeting NOS3 in secondary pneumococcal pneumonia

Secondary pneumococcal pneumonia remains a major problem after primary influenza (2), and can be modeled by infecting mice with a non-lethal dose of influenza and then challenging the lungs with pneumococci 7 days later. This is a time period of maximal susceptibility to secondary infection (10, 11), as illustrated by the remarkably low dose of pneumococci needed to cause pneumonia (500 CFU) compared to the 100,000 CFU used in the primary pneumonia model. We evaluated the pharmacologic agents that proved effective in our primary pneumonia model for potential benefit to reduce susceptibility or severity of secondary pneumonia after influenza. We found that treatment of mice with statins substantially improved survival in a dose-dependent manner (Fig. 6A). We observed similar improved survival in mice treated with AVE3085 (Fig. 6B), and also found this treatment improved bacterial clearance measured at 24 hours after challenge (Fig. 6C).

Discussion

We sought to identify new approaches to enhancing innate immunity to bacterial pneumonia by investigating the basis for gender differences in resistance to pneumococcal pneumonia. We conclude that estrogen mediates greater host resistance to pneumonia in female mice via effects on the constitutively expressed NOS3 in lung macrophages. The basis for this conclusion includes data in mouse cells or models using pharmacologic agents, inhibitors and genetically deficient animals. A similar advantage is seen in female human primary AMs and estrogen-treated human macrophages. These observations identify a novel host defense mechanism and a function for the main NOS isoform found in normal human macrophages. Pharmacologic targeting of NOS3 with one type of drug already in clinical use (statins) and another small-molecule lead compound (AVE3085) led to improved bacterial clearance and improved survival from secondary pneumococcal pneumonia.

The mechanism(s) by which macrophage NOS3 contributes to improved killing of ingested bacteria include direct bactericidal mechanisms, either alone or in combination with superoxide (38), but NOS3 might also act to mediate salutary intracellular signaling events (39). The very low amounts of NO generated by macrophage NOS3 prompt the speculation that additional mechanisms act to amplify its contribution to bacterial killing. These may include increased trafficking of NOS3 after estrogen-mediated phosphorylation to phagosomes, selective triggering of calcium-dependent NOS3 production of NO around bacteria by phagocytosis-associated calcium fluxes, and combination of NO with superoxide to generate peroxynitrite, a potent microbicidal agent (40). These possibilities are not mutually exclusive. The data also show an interesting but unresolved finding of incomplete concordance between in vitro and in vivo results using NOS3-deficient mice. Specifically, NOS3 deficiency eliminated the female advantage entirely in studies of bacterial killing by AMs in vitro. In contrast, the female advantage in vivo was diminished by approximately half in NOS3-deficient mice. The mechanism(s) and significance of this persistent component of gender difference in mice are unknown and need further study.

Another aspect of our study that merits discussion is our use of a low-dose inoculum for the primary pneumonia model. This is intended to model the initial phase of pneumonia that

follows the most likely route: aspiration of nasopharyngeal pneumococci or other bacteria. However, the quantity and composition of bacteria that enter the lungs during nocturnal aspiration is unknown. Moreover, while the premise that this is how pneumonia starts in humans is logical, there exists no formal proof. Ultimately, whether this attempt at a pre-clinical model proves relevant will depend on how the results translate to the clinical setting.

The potential relevance of these findings to human biology is indeed supported by the epidemiologic findings that both statins and estrogen-replacement therapy reduced risk of lung infection in a large cohort of women. There are also interesting reports of association of NOS3 polymorphisms with risk of community-acquired pneumonia (41). However, we consider that the translational potential of these findings may be most relevant for the problem of secondary pneumonia, specifically the increased susceptibility to bacterial lung infections that follows influenza. Using pre-treatment before the bacterial challenge is arguably a limitation of our studies in the primary pneumonia model; this approach is useful for proof-of-principle but does not mirror likely clinical usage. In contrast, pre-treatment in the secondary pneumonia model does represent a realistic scenario for short-term, prophylactic immunomodulatory therapy. This approach could boost resistance to prevent bacterial pneumonias during intervals of increased susceptibility. This could well benefit patients who are identified to be at high risk of secondary pneumonia, e.g. hospitalized individuals with severe seasonal or pandemic influenza.

Materials and Methods

Study design

This study began by seeking to characterize the basis for greater female resistance to pneumococcal pneumonia. A murine model of pneumococcal pneumonia was used to compare male and female bacterial clearance, lung inflammation and survival in vivo. In vitro assays of macrophage anti-bacterial function were used to identify killing of internalized bacteria as a critical difference. Pharmacologic inhibitors, genetic mouse models, and in vitro macrophage studies were used to investigate the role of oxidant-generating enzyme systems and estrogen. After identification of NOS3 as an important mediator, we tested pharmacologic agents with translational potential for ability to improve outcomes in primary and post-influenza secondary pneumococcal pneumonia. For in vivo studies, we used male and female mice of the same age,

and the studies were not blinded. Sample sizes for all of the experiments were sufficient to detect statistically significant differences between treatment groups, with all measurements included in analyses. To explore whether the effects of estrogen and statins that were observed in the murine models also occur in people, we studied incidence of hospitalized pneumonia associated with use of estrogen and statins in a population-based case-control study based on medical databases in Denmark. Cases of pneumonia were identified as all women who received a first-time principal hospital diagnosis of pneumonia in the former North Jutland and Aarhus Counties, Northern Denmark (1.2 million inhabitants) between 1997 and 2012. Using the Danish Civil Registration System, each case subject was matched with five population control subjects with same age, female gender, and residence in Northern Denmark on the pneumonia index date. We ascertained use of estrogen and statins in all individuals from population-based prescription databases. To control for confounding by other conditions potentially associated with both estrogen and statin use and pneumonia risk, we retrieved individual-level data on 19 major comorbid disease categories as evidenced in the Charlson comorbidity index, as well as on alcoholism-related conditions, recent antibiotic use, and marital status as a marker of socioeconomic status. We then computed odds ratios (ORs) for a first-time pneumonia admission among women with and without estrogen and statin use, using conditional logistic regression analysis to control for confounders.

Mouse models of pneumococcal pneumonia

Normal eight- to 12-week-old male and female mice C57BL/6 mice from Charles River Laboratories (Wilmington, MA) or Jackson Laboratories (Bar Harbor, ME) were used. C57BL/6 mice genetically deficient in nitric oxide synthase 2 (42), nitric oxide synthase 3 (43) and NADPH oxidase (19) were obtained from Jackson Laboratories (Bar Harbor, ME). Mice transgenic for human NOS3 were previously characterized (44). All animals were housed in sterile microisolator cages in a barrier facility and had no evidence of spontaneous infection. Prior approval for all experimentation was obtained from the institutional animal use review committee

Primary pneumococcal pneumonia was modeled as previously reported (45). Pneumonia was induced by intranasal instillation (i.n.) of 25 μ l of a bacterial suspension containing

324 approximately 10^5 colony-forming units (CFU) of *S. pneumoniae* type 3 of mice under short-
325 term anesthesia with inhaled isoflurane. The bacterial suspension was prepared to contain 10^5
326 CFU based on optical density calculations. However, results of direct validation of actual CFU
327 in these samples was always performed and showed actual CFU values that ranged from 90 -110
328 % of the calculated 10^5 CFU value. Hence, the dose delivered is stated as $\sim 10^5$ CFU. For analysis
329 at 4 or 24 h post-infection, mice were sacrificed with by lethal overdose of intraperitoneal
330 sodium pentobarbital (FatalPlus, Vortech Pharmaceuticals, Dearborn, MI) or by excess inhaled
331 isoflurane. To measure total lung bacteria counts (CFU), whole lungs were harvested and
332 homogenized in 1 ml sterile water with a tissue homogenizer (Omni International, Warrenton,
333 VA). Serial 10-fold dilutions in sterile water were made from these homogenates, and 100 μ l
334 volumes were plated onto sheep-blood agar plates and incubated at 37°C. CFUs were counted
335 after 18-20 hours. In experiments to assess survival, mice were instilled i.n. with a single 25 μ l
336 suspension containing a higher dose of *S. pneumoniae* ($\sim 3 \times 10^5$ CFU) and survival followed as
337 reported in Results. For analysis of lung inflammation, bronchoalveolar lavage was performed *in*
338 *situ* with a 22-gauge catheter inserted into the proximal trachea, flushing the lower airways six
339 times with 0.7 ml of phosphate-buffered saline (PBS). The fluid retrieved from the first lavage
340 was kept for ELISA assays. The BAL cells were separated from the BAL fluid by centrifugation,
341 resuspended in PBS and counted. A fraction was cytospun on microscopic slides for staining
342 with Diff-Quick (Baxter Scientific Products, McGaw Park, IL) for subsequent differential
343 counts. In initial experiments, male mice were analyzed 20 days after subcutaneous implantation
344 according to manufacturer's instructions of slow-release 17-beta-estradiol pellets (~ 70 ug/day,
345 Innovative Research, Sarasota, FL). In later experiments, mice received a single dose of estradiol
346 by inhalation exposure for 1 hour to an aerosol generated from a solution of E2-BSA β -Estradiol
347 6-(O-carboxymethyl)oxime: BSA (75 ng/ml aerosol solution, ~ 30 mol steroid per mol BSA,
348 Sigma) using the mouse exposure system described in (46). Drug treatments to assess effects on
349 24 hour bacterial clearance were administered 4h before, and 8 and 20 hours after bacterial
350 challenge included i.p. pravastatin 50-100 mg/kg, and 1400W 10 mg/kg. The NOS3 activator
351 AVE3085 (2,2-difluoro-benzo[1,3]dioxole-5- carboxylic acid indan-2-ylamide, CAS no.
352 450348-85-3; empirical formula $C_{17}H_{13}F_2NO_3$; (37)) was administered by gavage at 100
353 mg/kg/day for 3 days prior to challenge or by subcutaneous injection of 0.75 mg 24 and 3 hours

before challenge.

To model post-influenza secondary pneumonia, mice were instilled i.n. on day 0 with a single 25 μ l or 50 μ l suspension containing influenza virus (A/PR 8/34; H1N1), under general anesthesia by i.p. ketamine (120 mg/kg) plus xylazine (16 mg/kg). Influenza-treated animals routinely lost weight and then recovered by day 7, when the secondary infection was administered. On day 7 after initial influenza infection, mice were subjected to the same anesthesia, and then instilled i.n. with a single 25 μ l of bacterial suspension containing approximately 500 CFU of *S. pneumoniae* type 3. Pravastatin (50-100 mg/kg i.p.) or AVE3085 (0.75 mg s.c.) was administered daily starting one day before pneumococcal challenge. Subsequent analyses were performed as for the primary pneumonia model described above.

Cell isolation and culture

After euthanasia, mouse AMs obtained by repeated lung lavage with sterile PBS were centrifuged at 150 x g and resuspended in HBSS⁺ (Hanks' Buffered Salt Solution with calcium, 0.3 mM, and magnesium, 1 mM). Primary mouse AMs were used immediately without exposure to culture media components that contain estrogen (e.g. serum) or (weakly) estrogenic phenol red. The mouse and human macrophage cell lines J774A.1 and U937 were obtained from ATCC and maintained in phenol-free RPMI with 10% FBS. In experiments testing effects of estrogen addition in vitro, a charcoal-stripped FBS (Hyclone, Logan, UT) was used for macrophage culture to eliminate exposure to serum hormones. Human alveolar macrophages were obtained from non-smoking volunteers by bronchoalveolar lavage and resuspended in HBSS⁺ when tested immediately or cultured in phenol-free RPMI with 10% fetal bovine serum (FBS) overnight. The potential confounding effects of estrogen in FBS were not observed in human AM samples cultured overnight, i.e. gender differences observed in cells used immediately after isolation were preserved. All human subject experimentation was conducted under approved protocols reviewed by the institutional review boards. Estrogen was added to macrophage cultures as β -Estradiol-Water Soluble (Sigma) at 0.05-0.3 ng/ml. All other reagents not otherwise specified were obtained from Sigma Chemical, St. Louis, MO.

Bacteria

Strep. pneumoniae serotype 3, *E. Coli*, *Staph. aureus* (#6303, 19138, 25923, respectively,

ATCC, Rockville, MD) were cultured overnight on 5% sheep blood-supplemented agar Petri dishes (VWR # 90001-282, West Chester, PA). A stock suspension was prepared, and aliquots kept at -80°C. For each experiment, an aliquot was grown overnight on a blood agar plate and re-suspended in sterile PBS. Bacterial concentration of the obtained suspension was estimated by OD₆₀₀ measurements, comparing to a prior standard curve of OD₆₀₀ vs. CFU. The appropriate dilution was prepared in sterile PBS to be administered to mice, and this estimate was checked in parallel by CFU assay to determine the precise concentration.

Phagocytosis and bacterial killing assay

Macrophage binding, internalization and killing of internalized bacteria were measured using CFU assays of cell samples lysed by 10-fold excess H₂O (pH 10, 3 minutes). Macrophages (1.5 X 10⁶ cells/ 1.5 ml HBSS⁺) were mixed with bacteria (15 X 10⁶ CFU,; 10 bacteria per 1 macrophage) for 1 hour at 37° C. After centrifugation the cell pellet was re-suspended and an aliquot taken to measure the total cell-associated CFU (bound and internalized). After brief incubation of the cell suspension with gentamicin (200 ug/ml, 15 minutes at 37° C) to kill external, bound bacteria, the macrophages were washed and an aliquot taken for lysis and CFU assay to quantitate the number of internalized, live bacteria. The macrophages were then incubated an additional hour to allow killing of internalized bacteria, and aliquots taken again for CFU quantitation. The CFU data obtained at various time points allows calculation of the number of bacteria bound, internalized and killed. Effects of pharmacologic inhibitors or hormones were tested by including agents or their vehicles in the assay buffers. Respiratory burst function in normal mouse AMs was measured by quantitation of the H₂O₂-catalyzed oxidation of Amplex Red (Molecular Probes, Eugene, OR) to a fluorescent product after stimulation with adsorbed antibodies (anti-FcR, CD18) or PMA (100 nM) as previously described (47).

Western blot and ELISA analysis

Western blot analysis was performed on macrophage lysates lysis buffer 1% NP-40 with protease and phosphatase inhibitors using the protocols described in (27). The endothelial cell line bEnd.3 (ATCC CRL-2299) was used as a positive control for ('endothelial') NOS3. Antibodies for NOS3, Akt and phosphorylation-state specific isoforms used include: NOS3

rabbit pAb (C-20, Santa Cruz Biotechnology) and phospho-eNOS (Ser1177,C9C3) rabbit mAb, phospho-Akt (Ser473, D9E) rabbit mAb, Akt rabbit pAb and Beta-Actin (13E5) rabbit mAb, all from Cell Signaling Technologies. After incubation with peroxidase-conjugated goat anti-rabbit IgG or goat anti-mouse IgG (Pierce), labeling was detected using chemiluminescence. Quantitation of digitized signal intensity data was performed using ImageJ software (<http://imagej.nih.gov>). Cytokines were quantitated in BAL fluid using commercially available ELISA kits (R&D Systems Inc., Minneapolis, MN) following the manufacturer's instructions.

Statistical analysis: Data were analyzed using the Prism software package (GraphPad Software). Differences in Kaplan-Meier survival curves were analyzed using a log-rank test. For most other measurements, differences between groups were examined by ANOVA with Tukey's multiple comparison test. For gel quantitation values, the visual impression of increased intensity was analyzed using one-way t-tests. Data are presented as mean \pm SD. Results were considered significant when *P* value was $<.05$.

Acknowledgments: We thank J. Stamler, T. Michel, J. Mizgerd, S. Matalon, and E. Kovacs for helpful discussion and advice, and J. Soukup for technical assistance. **Funding:** This research was supported by NIH HL083436, ES0002 and the Flight Attendant Medical Research Institute.

References.

References.

1. J. P. Mizgerd. 2006 Lung infection--a public health priority. *PLoS Medicine*. 3(2):e76. doi: 10.1371/journal.pmed.0030076
2. S. Shrestha, B. Foxman, D. M. Weinberger, C. Steiner, C. Viboud and P. Rohani. 2013 Identifying the interaction between influenza and pneumococcal pneumonia using incidence data. *Sci Trans Med*. 5(191):191ra84. doi: 10.1126/scitranslmed.3005982
3. K. Gleeson, D. F. Egli and S. L. Maxwell. 1997 Quantitative aspiration during sleep in normal subjects. *Chest*. 111(5):1266-1272.
4. D. H. Dockrell, M. K. B. Whyte and T. J. Mitchell. 2012 Pneumococcal pneumonia: mechanisms of infection and resolution. *Chest*. 142(2):482-491. doi: 10.1378/chest.12-0210
5. E. S. Donkor. 2013 Understanding the pneumococcus: transmission and evolution. *Front Cell Infect Microbiol*. 3(7. doi: 10.3389/fcimb.2013.00007
6. G. M. Green and E. H. Kass. 1964 The Role of the Alveolar Macrophage in the Clearance of Bacteria from the Lung. *J Exp Med*. 119(167-76.
7. A. O. Fels and Z. A. Cohn. 1986 The alveolar macrophage. *J Appl Physiol (1985)*. 60(2):353-69.
8. T. Hussell and T. J. Bell. 2014 Alveolar macrophages: plasticity in a tissue-specific context. *Nat Rev Immunol*. 14(2):81-93. doi: 10.1038/nri3600
9. D. H. Dockrell, H. M. Marriott, L. R. Prince, V. C. Ridger, P. G. Ince, P. G. Hellewell and M. K. B. Whyte. 2003 Alveolar macrophage apoptosis contributes to pneumococcal clearance in a resolving model of pulmonary infection. *J Immunol*. 171(10):5380-5388.
10. H. E. Ghoneim and J. A. McCullers. 2013 Adjunctive corticosteroid therapy improves lung immunopathology and survival during severe secondary pneumococcal pneumonia in mice. *The J Inf Dis*.jit653. doi: 10.1093/infdis/jit653
11. K. Sun and D. W. Metzger. 2008 Inhibition of pulmonary antibacterial defense by interferon-gamma during recovery from influenza infection. *Nat Med*. 14(5):558-64. doi: 10.1038/nm1765
12. H. S. Weiss, B. Angrick, F. Pitt and N. L. Somerson. 1973 Sex difference in susceptibility of mice to pneumococcus. *Experientia*. 29(3):374-5.

13. A. Kadioglu, A. M. Cuppone, C. Trappetti, T. List, A. Spreafico, G. Pozzi, P. W. Andrew and M. R. Oggioni. 2011 Sex-based differences in susceptibility to respiratory and systemic pneumococcal disease in mice. *J Inf Dis*. 204(12):1971-1979. doi: 10.1093/infdis/jir657
14. E. E. McClelland and J. M. Smith. 2011 Gender specific differences in the immune response to infection. *Arch Immunol Therap Exp*. 59(3):203-213. doi: 10.1007/s00005-011-0124-3
15. F. Gutiérrez, M. Masiá, C. Mirete, B. Soldán, J. C. Rodríguez, S. Padilla, I. Hernández, G. Royo and A. Martín-Hidalgo. 2006 The influence of age and gender on the population-based incidence of community-acquired pneumonia caused by different microbial pathogens. *J Infect*. 53(3):166-174. doi: 10.1016/j.jinf.2005.11.006
16. C. J. Gannon, M. Pasquale, J. K. Tracy, R. J. McCarter and L. M. Napolitano. 2004 Male gender is associated with increased risk for postinjury pneumonia. *Shock*. 21(5):410-414.
17. J. Andermahr, A. Greb, T. Hensler, H. J. Helling, B. Bouillon, S. Sauerland, K. E. Rehm and E. Neugebauer. 2002 Pneumonia in multiple injured patients: a prospective controlled trial on early prediction using clinical and immunological parameters. *Inflamm Res*. 51(5):265-272. doi: 10.1007/PL00000303
18. P. J. Offner, E. E. Moore and W. L. Biffl. 1999 Male gender is a risk factor for major infections after surgery. *Arch Surgery*. 134(9):935-8
19. D. E. Morgenstern, M. A. Gifford, L. L. Li, C. M. Doerschuk and M. C. Dinauer. 1997 Absence of respiratory burst in X-linked chronic granulomatous disease mice leads to abnormalities in both host defense and inflammatory response to *Aspergillus fumigatus*. *J Exp Med*. 185(2):207-218. doi: 10.1084/jem.185.2.207
20. L. Connelly, A. T. Jacobs, M. Palacios-Callender, S. Moncada and A. J. Hobbs. 2003 Macrophage endothelial nitric-oxide synthase autoregulates cellular activation and pro-inflammatory protein expression. *J Biol Chem*. 278(29):26480-26487. doi: 10.1074/jbc.M302238200
21. P. R. Miles, L. Bowman, A. Rengasamy and L. Huffman. 1998 Constitutive nitric oxide production by rat alveolar macrophages. *Am J Physiol Lung Cell Mol Physiol*. 274(3):L360-L368. doi: 10.1016/0049-3848(87)90361-6
22. J. F. van Straaten, D. S. Postma, W. Coers, J. A. Noordhoek, H. F. Kauffman and W. Timens. 1998 Macrophages in lung tissue from patients with pulmonary emphysema express both inducible and endothelial nitric oxide synthase. *Mod Pathol*. 11(7):648-55.
23. C. Nathan and M. U. Shiloh. 2000 Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. *Proc Natl Acad Sci U S A*. 97(16):8841-8.

24. G. M. Buga, J. M. Griscavage, N. E. Rogers and L. J. Ignarro. 1993 Negative feedback regulation of endothelial cell function by nitric oxide. *Circ Res.* 73(5):808-812. doi: 10.1161/01.RES.73.5.808
25. P. A. Erwin, A. J. Lin, D. E. Golan and T. Michel. 2005 Receptor-regulated dynamic S-nitrosylation of endothelial nitric-oxide synthase in vascular endothelial cells. *J Biol Chem.* 280(20):19888-19894. doi: 10.1074/jbc.M413058200
26. G. B. Stefano, V. Prevot, J. C. Beauvillain, C. Fimiani, I. Welters, P. Cadet, C. Breton, J. Pestel, M. Salzet and T. V. Bilfinger. 1999 Estradiol coupling to human monocyte nitric oxide release is dependent on intracellular calcium transients: evidence for an estrogen surface receptor. *J Immunol.* 163(7):3758-63.
27. E. Gonzalez, R. Kou, A. J. Lin, D. E. Golan and T. Michel. 2002 Subcellular targeting and agonist-induced site-specific phosphorylation of endothelial nitric-oxide synthase. *J Biol Chem.* 277(42):39554-60.
28. K. L. Chambliss and P. W. Shaul. 2002 Estrogen modulation of endothelial nitric oxide synthase. *Endo Rev.* 23(5):665-686. doi: 10.1210/er.2001-0045
29. S. P. Duckles and V. M. Miller. 2010 Hormonal modulation of endothelial NO production. *Pflug Archiv : Eur J Physiol.* 459(6):841-851. doi: 10.1007/s00424-010-0797-1
30. K. Takeuchi and F. Ito. 2004 Suppression of adriamycin-induced apoptosis by sustained activation of the phosphatidylinositol-3'-OH kinase-Akt pathway. *J Biol Chem.* 279(2):892-900.
31. J. Studd, B. Pornel, I. Marton, J. Bringer, C. Varin, Y. Tsouderos and C. Christiansen. 1999 Efficacy and acceptability of intranasal 17 beta-oestradiol for menopausal symptoms: randomised dose-response study. Aerodioid Study Group. *Lancet.* 353(9164):1574-8.
32. R. R. Muder. 1998 Pneumonia in residents of long-term care facilities: epidemiology, etiology, management, and prevention. *Am J Med.* 105(4):319-330. doi: 10.1016/S0002-9343(98)00262-9
33. T. R. Chakraborty and A. C. Gore. 2004 Aging-related changes in ovarian hormones, their receptors, and neuroendocrine function. *Exp Biol Med.* 229(10):977-987. doi:
34. U. Forstermann and H. Li. 2011 Therapeutic effect of enhancing endothelial nitric oxide synthase (eNOS) expression and preventing eNOS uncoupling. *Br J Pharmacol.* 164(2):213-23. doi: 10.1111/j.1476-5381.2010.01196.x
35. R. W. Thomsen, A. Riis, J. B. Kornum, S. Christensen, S. P. Johnsen and H. T. Sorensen. 2008 Preadmission use of statins and outcomes after hospitalization with pneumonia: population-based cohort study of 29,900 patients. *Arch Int Med.* 168(19):2081-7. doi: 10.1001/archinte.168.19.2081

36. A. G. Nielsen, R. B. Nielsen, A. H. Riis, S. P. Johnsen, H. T. Sørensen and R. W. Thomsen. 2012 The impact of statin use on pneumonia risk and outcome: a combined population-based case-control and cohort study. *Crit Care*. 16(4):R122. doi: 10.1186/cc11418
37. P. Wohlfart, H. Xu, A. Endlich, A. Habermeier, E. I. Closs, T. Hubschle, C. Mang, H. Strobel, T. Suzuki, H. Kleinert, U. Forstermann, H. Ruetten and H. Li. 2008 Antiatherosclerotic effects of small-molecular-weight compounds enhancing endothelial nitric-oxide synthase (eNOS) expression and preventing eNOS uncoupling. *J Pharmacol Exp Ther*. 325(2):370-9. doi: 10.1124/jpet.107.128009
38. F. C. Fang. 2004 Antimicrobial reactive oxygen and nitrogen species: concepts and controversies. *Nat Rev Microbio*. 2(10):820-832. doi: 10.1038/nrmicro1004
39. P. Hernansanz-Agustín, A. Izquierdo-Álvarez, A. García-Ortiz, S. Ibiza, J. M. Serrador and A. Martínez-Ruiz. 2013 Nitrosothiols in the immune system: signaling and protection. *Antioxid Redox Sign*. 18(3):288-308. doi: 10.1089/ars.2012.4765
40. P. A. Darrah, M. K. Hondalus, Q. Chen, H. Ischiropoulos and D. M. Mosser. 2000 Cooperation between reactive oxygen and nitrogen intermediates in killing of *Rhodococcus equi* by activated macrophages. *Inf Immun*. 68(6):3587-3593. doi:
41. L. E. Salnikova, T. V. Smelaya, V. V. Moroz, A. M. Golubev and A. V. Rubanovich. 2013 Host genetic risk factors for community-acquired pneumonia. *Gene*. 518(2):449-56. doi: 10.1016/j.gene.2012.10.027
42. V. E. Laubach, E. G. Shesely, O. Smithies and P. A. Sherman. 1995 Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. *Proceedings of the National Academy of Sciences of the United States of America*. 92(23):10688-10692. doi:
43. E. G. Shesely, N. Maeda, H. S. Kim, K. M. Desai, J. H. Krege, V. E. Laubach, P. A. Sherman, W. C. Sessa and O. Smithies. 1996 Elevated blood pressures in mice lacking endothelial nitric oxide synthase. *Proc Natl Acad Sci U S A*. 93(23):13176-81.
44. S. P. Jones, J. J. Greer, R. van Haperen, D. J. Duncker, R. de Crom and D. J. Lefer. 2003 Endothelial nitric oxide synthase overexpression attenuates congestive heart failure in mice. *Proc Natl Acad Sci U S A*. 100(8):4891-6. doi: 10.1073/pnas.0837428100
45. M. Arredouani, Z. Yang, Y. Ning, G. Qin, R. Soininen, K. Tryggvason and L. Kobzik. 2004 The scavenger receptor MARCO is required for lung defense against pneumococcal pneumonia and inhaled particles. *J Exp Med*. 200(2):267-272. doi: 10.1084/jem.20040731
46. K. Hamada, Y. Suzuki, A. Goldman, Y. Y. Ning, C. Goldsmith, A. Palecanda, B. Coull, C. Hubeau and L. Kobzik. 2003 Allergen-independent maternal transmission of asthma susceptibility. *J Immunol*. 170(4):1683-1689. doi:

615 47. S. Józefowski and L. Kobzik. 2004 Scavenger receptor A mediates H₂O₂ production and
616 suppression of IL-12 release in murine macrophages. *J Leuk Biol.* 76(5):1066-1074. doi:
617 10.1189/jlb.0504270
618
619
620
621

622

623 **Figure Titles and Legends.**

624 Figure 1. Females show greater resistance to pneumococcal pneumonia.

625 (A) Twenty-four hours after intranasal (i.n.) inoculation of *Strep. pneumoniae* ($\sim 10^5$ CFU), lung
626 samples from female mice (and estrogen-treated male mice via subcutaneous slow-release 17-
627 beta-estradiol pellets, ~ 70 ug/day) contain fewer live bacteria than seen in male mice ($n \geq 12$, $* =$
628 $p < .01$ vs. control or sham-treated males) and (B) show less acute inflammation (BAL
629 neutrophils, $n \geq 12$, $* = p < .01$). C) After i.n. pneumococcus, female mice show significantly
630 greater survival than male mice (2.5×10^5 CFU, $n \geq 24$, $* = p < .01$). Gender differences in
631 pneumonic inflammation are seen with low (4×10^5 CFU), but not high (11×10^5), bacterial
632 inocula, measured as BAL neutrophilia (D) or BAL cytokines TNF (E), MIP-2 (F), or IL-6 (G),
633 ($n \geq 3$, $* = p < .05$).

634

635 Figure 2. Female alveolar macrophages show better killing of ingested bacteria.

636 Binding (A) and internalization (B) of *Strep. pneumoniae* in normal male and female AMs is
637 similar. Female AMs kill more internalized bacteria than male AMs in assays using pneumococci
638 (C) ($n \geq 11$, $* = p < .01$), *Staph. aureus* (D) or *E. Coli* (E), ($n \geq 3$, $* = p < .01$). (F). Normal
639 human female AMs also show greater killing of internalized pneumococci ($n \geq 5$, $* = p < .01$).

640

641 Figure 3. NOS3 and female resistance to pneumococcal pneumonia. (A) NADPH oxidase
642 deficient (*phox91*^{-/-}) mice show comparable reduction in bacterial clearance in both male and
643 female mice ($n = 6$, $* = p < .01$ vs wild-type). (B) In vitro killing of pneumococci by normal
644 mouse female AMs is inhibited by the non-selective NOS inhibitor nitro-L-arginine (NLA), but
645 not by its inactive stereo-isomer, nitro-D-arginine (NDA), nor by the type 2 NOS specific
646 inhibitor 1400W ($n = 3-4$, $* = p < .01$). (C) Female AMs from *Nos3*^{-/-} mice lose the in vitro
647 killing advantage of wild-type female AMs, and show the same killing rate as wild-type or NOS3
648 deficient male AMs ($n = 3$, $* = p < .01$ vs. wild-type). (D) In vivo, absence of NOS3 reduces, but
649 does not completely eliminate, the female advantage in bacterial clearance ($n = 15$, $* = p \leq .015$
650 vs. all 3 other groups), and results in increased mortality from pneumococcal pneumonia (E) ($n =$
651 12 female mice per group, $* = p < .01$). Conversely, transgenic male mice with increased
652 expression of human NOS3 show enhanced killing of *Strep. pneumoniae* in vivo (lower bacterial
653 survival, $n \geq 5$, $* = p < .01$). In this low-dose inoculum model, NOS2 deletion (G) or inhibition
654 (H) causes reduced bacterial clearance in male, but not female mice. ($n = 8$, $* = p < .05$).

655

656 Fig. 4. Estrogen-mediated activation of macrophage NOS3. Estrogen treatment of J774A.1
657 mouse or human U937 macrophages (A, B) increases killing of ingested pneumococci; this
658 increased killing is prevented by the NOS inhibitors NLA or l-NMMA, but not control
659 stereoisomers ($n = 3-4$, $* = p < .01$). (C) Western blot analysis shows >100 -fold less NOS3 in
660 macrophages compared to the endothelial cell line bEnd.1; after 30 minutes, estrogen-treated
661 (E2, estradiol, 0.2 ng/ml) J774A.1 mouse macrophages show increased phosphorylation of Akt
662 and NOS 3, while normal female AMs show basally increased pAkt and pNOS3 compared to
663 male AMs; (D) Basal and estrogen-enhanced phosphorylation of Akt and NOS3 are inhibited by
664 wortmannin (Wm, 50 nM). (E) Inhibition of Akt with 1L-6-hydroxymethyl-chiro-inositol 2-(R)-
665 2-O-methyl-3-O-octadecylcarbonate (10 ug/ml REF) prevents estrogen-mediated increased

bacterial killing in J774A.1 cells ($n = 3$, $* = p < .01$). (F) Aerosol pre-treatment of male mice with albumin-conjugated estrogen 30 minutes before pneumococcal infection improves bacterial killing ($n = 6$, $* = p < .01$). (G) In ovariectomy-model of menopause, female mice lose their greater resistance to pneumococcal pneumonia after 10 weeks, an effect reversed by treatment with estrogen prior to infection $n \geq 8$ for control, 10 week groups; $n = 3$ for 2 and 5 week groups; $* = p < .01$.

Fig. 5. Statins enhance innate immune resistance to *Strep. pneumoniae* via NOS3. (A) In vitro treatment of J774A.1 mouse macrophages with mevastatin (5 μ M) increases levels of pNOS3 and NOS3, and (B) concomitantly increases killing of internalized bacteria ($n = 4$, $* = p < .01$). (C) In vivo, pre-treatment of mice with pravastatin (50 mg/kg) significantly improves bacterial clearance in wild-type mice ($n = 8$, $* = p < .01$ vs. male controls; $** = p < .01$ vs. males, males + statin) but has no significant effect on either male or female NOS3^{-/-} mice. (D) Statin-treated male mice with pneumococcal pneumonia show improved survival ($n = 8$, $* = p < .01$). (E) AVE3085, a small molecule activator of NOS3, increases bacterial killing by mouse macrophages in vitro ($n = 3$, $* = p < .01$) (F) Pre-treatment of male mice with AVE3085 by either subcutaneous or oral route improves in vivo bacterial clearance, an effect not seen in NOS3^{-/-} male mice ($n = 3-8$, $* = p < .01$).

Fig. 6. Statins and AVE3085 improve survival from post-influenza secondary pneumococcal pneumonia. Male mice were allowed to recover 7 days from mild influenza (PR8 1 PFU i.n.), and then challenged with *Strep. pneumoniae* (500 CFU i.n.). Pre-treatment with (A) pravastatin (50 or 100 mg/kg) or (B) AVE3085 (0.75 mg, s.c.) caused a significant improvement in survival ($n = 10$, $* = p < .01$). C) AVE3085 treatment also lead to improved bacterial clearance 24 hours after pneumococcal challenge in this post-influenza model ($n = 6$, $* = p < .01$).

Table 1.

Table 1. Characteristics of 28, 576 female subjects with first-time hospitalized pneumonia and 142 880 age-matched female population control subjects from Northern Denmark, 1997–2012

Characteristic at time of pneumonia admission	Pneumonia cases	Population controls	Total
<i>n</i>	28 576	142 880	171 456
Age			
15–39 years	2006 (7.0)	10062 (7.0)	12068 (7.0)
40–64 years	6383 (22.3)	32023 (22.4)	38406 (22.4)
65–79 years	9871 (34.5)	49267 (34.5)	59138 (34.5)
≥80 years	10316 (36.1)	51528 (36.1)	61844 (36.1)
Charlson Comorbidity Index			
Index low (0)	12031 (42.1)	100297 (70.2)	112328 (65.5)
Index medium (1-2)	11324 (39.6)	34896 (24.4)	46220 (27.0)
Index high (≥3)	5221 (18.3)	7687 (5.4)	12908 (7.5)
Alcoholism-related conditions	1398 (4.9)	2225 (1.6)	3623 (2.1)
Preadmission medication use			
Antibiotic use (≤ 3 months)	12778 (44.7)	20002 (14.0)	32780 (19.1)
Statins, current use (≤ 6 months)	3506 (12.3)	16111 (11.3)	19617 (11.4)
Estrogen, current use (≤ 6 months)	2592 (9.1)	13225 (9.3)	15817 (9.2)
Statins and estrogen, current use (≤ 6 months)	509 (1.8)	2509 (1.8)	3018 (1.8)
Statins and estrogen, no current use	21969 (76.9)	111035 (77.7)	133004 (77.6)
Marital status			
Married	10109 (35.4)	57673 (40.4)	67782 (39.5)
Never married	2825 (9.9)	13523 (9.5)	16348 (9.5)
Divorced or widowed	15642 (54.7)	71684 (50.2)	87326 (50.9)

Table 2.

Table 2. Odds-Ratios for first-time hospitalized pneumonia associated with current use of statins alone, estrogen alone, and estrogen + statins in combination

Statin use	Pneumonia cases (n=28,576)	Matched population controls (n=142,880)	Crude OR (95% CI)*	Adjusted OR (95% CI)**
No current use of statins or estrogen	21969 (76.9)	111035 (77.7)	1.0 (reference)	1.0 (reference)
Current use of statins (≤ 180 days before admission)	3506 (12.3)	16111 (11.3)	1.12 (1.07-1.16)	0.82 (0.78–0.85)
Current use of estrogen (≤ 180 days before admission)	2592 (9.1)	13225 (9.3)	0.99 (0.95-1.04)	0.82 (0.78–0.86)
Current use of both statins and estrogen (≤ 180 days before admission)	509 (1.8)	2509 (1.8)	1.04 (0.94-1.15)	0.67 (0.60–0.75)

*Matched for age and hospitalization date.

**Adjusted for level of Charlson's comorbidity index (19 different comorbidities), alcoholism-related conditions, antibiotics before admission, and marital status (see Table 1).

Figure Supplements:

Figure 1-figure supplement 1. Respiratory burst by male and female alveolar macrophages. Stimulation of normal AMs by antibodies to 2 different surface receptors (FcR, CD18) or with PMA leads to approximately equal increases in H_2O_2 release in both male and female AMs, indicating absence of gender differences in production of reactive oxygen species.

712

713











